Abstract
Vasculopathy in patients with connective tissue diseases (CTDs), including systemic sclerosis (SSc) and systemic lupus erythematosus (SLE), is a serious complication that mainly affects small arteries and capillaries, reduces the blood flow and causes progressive tissue ischemia. Recently, CTD patients have been reported to have abnormalities in circulating endothelial progenitor cells (EPCs); these abnormalities are believed to contribute to the pathophysiology of vasculopathy and to the premature and accelerated development of atherosclerosis in CTD patients. Furthermore, we are currently conducting a clinical pilot study to determine the efficacy of implanting autologous mononuclear cells obtained from the bone marrow and peripheral blood into the ischemic digits or limbs of CTD patients. In this review, we discuss the role of EPCs in the process of neovascularization and in the pathophysiology of CTDs, and we describe a clinical pilot study on the use of autologous cell therapy for treating ischemic digits in patients with CTDs.
Keywords: Angiogenesis, mononuclear cells, connective tissue disease, EPCs, ischemia, scleroderma, vasculopathy
Current Pharmaceutical Design
Title: Therapeutic Neovascularization by the Implantation of Autologous Mononuclear Cells in Patients with Connective Tissue Diseases
Volume: 15 Issue: 24
Author(s): Masafumi Takahashi, Atsushi Izawa, Yoshiaki Ishigatsubo, Kazuteru Fujimoto, Masaaki Miyamoto, Takashi Horie, Yoshifusa Aizawa, Jun Amano, Seiji Minota, Toyoaki Murohara, Hiroaki Matsubara and Uichi Ikeda
Affiliation:
Keywords: Angiogenesis, mononuclear cells, connective tissue disease, EPCs, ischemia, scleroderma, vasculopathy
Abstract: Vasculopathy in patients with connective tissue diseases (CTDs), including systemic sclerosis (SSc) and systemic lupus erythematosus (SLE), is a serious complication that mainly affects small arteries and capillaries, reduces the blood flow and causes progressive tissue ischemia. Recently, CTD patients have been reported to have abnormalities in circulating endothelial progenitor cells (EPCs); these abnormalities are believed to contribute to the pathophysiology of vasculopathy and to the premature and accelerated development of atherosclerosis in CTD patients. Furthermore, we are currently conducting a clinical pilot study to determine the efficacy of implanting autologous mononuclear cells obtained from the bone marrow and peripheral blood into the ischemic digits or limbs of CTD patients. In this review, we discuss the role of EPCs in the process of neovascularization and in the pathophysiology of CTDs, and we describe a clinical pilot study on the use of autologous cell therapy for treating ischemic digits in patients with CTDs.
Export Options
About this article
Cite this article as:
Takahashi Masafumi, Izawa Atsushi, Ishigatsubo Yoshiaki, Fujimoto Kazuteru, Miyamoto Masaaki, Horie Takashi, Aizawa Yoshifusa, Amano Jun, Minota Seiji, Murohara Toyoaki, Matsubara Hiroaki and Ikeda Uichi, Therapeutic Neovascularization by the Implantation of Autologous Mononuclear Cells in Patients with Connective Tissue Diseases, Current Pharmaceutical Design 2009; 15 (24) . https://dx.doi.org/10.2174/138161209788923813
DOI https://dx.doi.org/10.2174/138161209788923813 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiac Monitoring in Patients with Syncope: Making that Elusive Diagnosis
Current Cardiology Reviews Pharmacological and Clinical Applications of Natriuretic Peptides: Accepted Knowledges or Changing Views?
Current Pharmaceutical Analysis Tachykinins and their Receptors in Human Malignancies
Current Drug Targets Modern Developments in the Spray-Drying Industries
Recent Patents on Materials Science Antihypertensive Drug Treatment and Circadian Blood Pressure Rhythm: A Review of the Role of Chronotherapy in Hypertension
Current Pharmaceutical Design Cellular Cardiomyoplasty and Cardiac Regeneration
Current Cardiology Reviews Microalbuminuria: A Neglected Cardiovascular Risk Factor in Non-diabetic Individuals?
Current Pharmaceutical Design Systematic Review of Public Education and Policy for Stroke Prevention
Current Drug Targets Targeting Cyclooxygenase and Nitric Oxide Pathway Cross-Talk: A New Signal Transduction Pathway for Developing More Effective Anti- Inflammatory Drugs
Current Signal Transduction Therapy Endocytosis, Intracellular Traffic and Fate of Cell Penetrating Peptide Based Conjugates and Nanoparticles
Current Pharmaceutical Design Strain Imaging Echocardiography: What Imaging Cardiologists Should Know
Current Cardiology Reviews Editorial: Emerging Pharmacological Strategies for the Prevention of Atherosclerotic Disease Progression
Current Drug Targets - Cardiovascular & Hematological Disorders New Development and Application of Ultrasound Targeted Microbubble Destruction in Gene Therapy and Drug Delivery
Current Gene Therapy Morphology of Atherosclerotic Plaque: Its Feature by Imaging Study
Current Pharmaceutical Design Editorial (Epigenetics: A Paradigm Shift in Understanding Alzheimer’s Disease)
Current Alzheimer Research Diminished Renal Function and the Incidence of Heart Failure
Current Cardiology Reviews Clinical Applications for Cardiovascular Magnetic Resonance Imaging at 3 Tesla
Current Cardiology Reviews Cathinone Neurotoxicity (“The “3Ms”)
Current Neuropharmacology Prognostic Value of White Blood Cell Counts and C-reactive Protein in Acute Ischemic Stroke Patients After Intravenous Thrombolysis
Current Neurovascular Research Big Pharma's Recent Challenges
Applied Clinical Research, Clinical Trials and Regulatory Affairs